IMPACT OF POLICY MEASURES AND GENERIC COMPETITION ON PHARMACEUTICAL EXPENDITURE IN BELGIUM

REFERENCES

• Ess SM, Schneeweiss S. Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21: 89–103.
   PubMed Web of Science ®Google Scholar
• Fraeyman J, Van Hal G, De Loof H, Remmen R, De Meyer RYG, Beutelds P. Poten-tial impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium. Acta Clin Belg 2012; 3:160–171.
   Google Scholar
• Dupont AG, Heller F. Generics and cost-effective prescribing in Belgium - does bioequivalence always translate in therapeutic equivalence? Acta Clin Belg 2009: 5:406–414.
   Google Scholar
• Simoens S. De Bruyn K, Bogaert M, Laekeman G. Pharmaceutical policy regard-ing generic drugs in Belgium. Pharmacoeconomics 2005; 23: 755–766.
   PubMed Web of Science ®Google Scholar
• Van Wilder P. Dupont AG. Introducing evidence-based medicine in reimburse-ment procedures: does it affect the outcome? Val Health 2008; 11: 784–787.
   PubMed Web of Science ®Google Scholar
• Van Wilder PB, Dupont AG. Reimbursement of medicines in Belgium: role of evidence-based medicine. Acta Clin Belg 2009; 64: 120–127.
   PubMed Web of Science ®Google Scholar
• Pechlivanoglou P. Van der veen WJ, Bos JH, Postma MJ. Analyzing generic and branded substitution patterns in the Netherlands using prescription data. BMC Health Services Research 2011; 11: 89.
   Web of Science ®Google Scholar
• Perry G. The European generic pharmaceutical market in review: 2006 and beyond. J Gener Med 2006; 4: 4–14.
   Google Scholar
• Garattini L, Tediosi F. A comparative analysis of generic markets in five European countries. Health Policy 2000; 51: 149–162.
   PubMed Web of Science ®Google Scholar
• Andersson KA, Petzold MG, Allebeck P. Carlsten A. Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years. BMC Health Services Research 2008; 8: 50.
   PubMed Web of Science ®Google Scholar
• Klok RM, Boersma C, Oosterhuis I, Visser ST, de Jong-Van den Berg LTW, Postma MJ. Switch patterns before and after patent expiry of omeprazole: a case study in the Netherlands. Aliment Pharmacol Ther 2000; 23: 1595–1600.
   Web of Science ®Google Scholar
• Haskins LS, Tomaszeski KJ, Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav 2005; 1:98–105.
   Web of Science ®Google Scholar
• Himmel W, Simmenroth-Nayda A, Niebling W et al. What do primary care patients think about generic drugs? Intl Clin Pharmacol Ther 2005; 43: 472–479.
   PubMed Web of Science ®Google Scholar
• Pereira JA, Holbrook AM, Dolovich L et al. Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians. Can J Clin Phar-macol 2005; 12: 229–239.
   Google Scholar
• Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ. Generic substitu-tion in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav 2008; 13: 525–530.
   Google Scholar
• GantherJM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc 2000; 40:378–383.
   Google Scholar
• Kalo Z, Muszbek N, Bodrogi J, Bidlo J. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 2007; 80: 402–413.
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescrib-ing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoeconomic outcomes Res 2010; 10:707–722.
   PubMed Web of Science ®Google Scholar
• Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of revcent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev Pharmacoeconomic outcomes Res 2009; 9: 475–484.
   PubMedGoogle Scholar
• Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM. Generic atorvastatin and health care costs. N Engl J Med 2012; 366: 201–204.
   PubMed Web of Science ®Google Scholar